No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
Ace-083 |
- |
- |
- |
- |
[2] 10, 113 |
2 |
Acetate |
Acetate |
- |
- |
- |
[40] 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
3 |
Acido ascorbico |
- |
- |
- |
- |
[1] 10 |
4 |
Acido ascorbico dc.it |
- |
- |
- |
- |
[1] 10 |
5 |
Ascorbic acid |
Ascorbic acid |
D00018 |
- |
- |
[2] 10, 97 |
6 |
Ascorbic acid (vitamin c) |
Ascorbic acid |
D00018 |
- |
- |
[1] 10 |
7 |
Ascorbic acid vit c |
Ascorbic acid |
D00018 |
- |
- |
[1] 10 |
8 |
Baclofen |
Baclofen |
D00241 |
[2] GABBR1, GABBR2 |
[7] Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
[5] 2, 10, 13, 18, 149 |
9 |
Cebion 500*20cpr mast 500mg |
- |
- |
- |
- |
[1] 10 |
10 |
Cebion 500mg 20cpr mast.aran |
- |
- |
- |
- |
[1] 10 |
11 |
Coenzyme q10 |
Ubidecarenone |
D01065 |
- |
- |
[10] 2, 6, 8, 10, 46, 57, 113, 193, 214, 215 |
12 |
D-sorbitol |
Sorbitol |
D00096 |
- |
- |
[1] 10 |
13 |
Elleone |
- |
- |
- |
- |
[1] 10 |
14 |
Flx-787-odt (orally disintegrating tablet) |
- |
- |
- |
- |
[1] 10 |
15 |
Md1003 |
- |
- |
- |
- |
[5] 2, 10, 13, 14, 20 |
16 |
Mexiletine |
Mexiletine |
D00639, D08215 |
[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
[5] 1, 2, 10, 113, 114 |
17 |
Naltrexone |
Naltrexone |
D02095, D05113 |
[3] OPRD1, OPRK1, OPRM1 |
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
[11] 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
18 |
Naltrexone hydrochloride |
Naltrexone |
D02095, D05113 |
[3] OPRD1, OPRK1, OPRM1 |
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
[7] 10, 40, 41, 42, 43, 44, 45 |
19 |
Non applicable |
- |
- |
- |
- |
[2] 10, 19 |
20 |
Pxt3003 |
- |
- |
- |
- |
[1] 10 |
21 |
Pxt3003 dose 1 |
- |
- |
- |
- |
[1] 10 |
22 |
Pxt3003 dose 2 |
- |
- |
- |
- |
[1] 10 |
23 |
Pxt3003 high dose |
- |
- |
- |
- |
[1] 10 |
24 |
Pxt3003 intermediate dose |
- |
- |
- |
- |
[1] 10 |
25 |
Pxt3003 low dose |
- |
- |
- |
- |
[1] 10 |
26 |
Rs-baclofen |
Baclofen |
D00241 |
[2] GABBR1, GABBR2 |
[7] Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
[1] 10 |
27 |
Sodio ascorbato dc.it |
- |
- |
- |
- |
[1] 10 |
28 |
Sorbitol |
Sorbitol |
D00096 |
- |
- |
[1] 10 |
29 |
Ulipristal |
Ulipristal |
D09567 |
[1] PGR |
[4] Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
[1] 10 |
30 |
Ulipristal acetate |
Ulipristal |
D09567 |
[1] PGR |
[4] Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
[1] 10 |
31 |
Vitamin c |
Ascorbic acid |
D00018 |
- |
- |
[5] 10, 192, 206, 211, 212 |